Street Calls of the Week: Upgrade for Shopify; Downgrades for AMD, Paramount
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
European equities traded in the US as American depositary receipts were trending sharply lower Friday, falling 1.3% to 1,404.81 on the S&P Europe Select ADR Index, which is set to end the week down 1.
Mereo BioPharma Prices $50 Million Offering
Mereo BioPharma (MREO) said Friday it priced an underwritten offering of about 12.5 million American depositary shares at $3.99 apiece for gross proceeds of about $50 million. The company said the off
Express News | Mereo BioPharma Discloses Pricing of $50M Underwritten Registered Direct Offering of American Depository Shares, At A Price Of $3.99 Per ADS; Each ADS Represents Five Ordinary Shares Of Mereo
Press Release: Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma
Baird Starts Mereo at Outperform, Sees Alvelestat as Underappreciated
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
European equities traded in the US as American depositary receipts were sharply lower late Thursday morning, falling 1.60% to 1,418.28 on the S&P Europe Select ADR Index. From continental Europe, the
Express News | Mereo Biopharma Group PLC : Baird Initiates Coverage With Outperform Rating; Price Target $8
Baird Initiates Mereo BioPharma(MREO.US) With Buy Rating, Announces Target Price $8
Baird analyst Jack Allen initiates coverage on $Mereo BioPharma(MREO.US)$ with a buy rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 31.7% and a t
Update: Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate
(Updates with stock movements in the headline and first paragraph) Ultragenyx Pharmaceutical (RARE) shares rose 7.5% and Mereo BioPharma Group (MREO) climbed 5.3% in recent Wednesday trading, a day af
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results.Streamline Health reported qu
Express News | Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were moving sharply higher late Wednesday morning, rising 1.59% to 1,445.87 on the S&P Europe Select ADR Index. From continental Euro
Sector Update: Health Care Stocks Rise Premarket Wednesday
Health care stocks rose in Wednesday's premarket hours with the Health Care Select Sector SPDR Fund (XLV) advancing by 0.3% and the iShares Biotechnology ETF (IBB) 0.7% higher recently. Ultragenyx Pha
Express News | Mereo BioPharma Shares Are Trading Higher After the Company and Ultragenyx Pharmaceutical Announced 14-month Results From the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study
Sector Update: Health Care
Health care stocks rose in Wednesday's premarket hours with the Health Care Select Sector SPDR Fund (XLV) advancing by 0.5% and the iShares Biotechnology ETF (IBB) 1.1% higher recently. Ultragenyx Pha
Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper Sandl
Mereo Spikes After Mid-stage Data for Ultragenyx-partnered Bone Disorder Therapy
Mereo BioPharma (NASDAQ:MREO) traded higher premarket Wednesday after the company and its partner Ultragenyx Pharmaceutical (NASDAQ:RARE) announced 14-month data from a Phase 2 portion of an ongoing Phase 2/3 trial for their bone disorder therapy setrusumab (UX143).
Mereo BioPharma Group Is Maintained at Buy by Needham
Mereo BioPharma Group Is Maintained at Buy by Needham
Mereo BioPharma Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/12/2024 79.95% Needham $6 → $7 Maintains Buy 05/16/2024 79.95% Cantor Fitzgerald $7 → $7 Reiterates Ove
No Data